Cogstate Limited, a neuroscience technology firm established in 1999 and headquartered in Melbourne, Australia, specializes in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. The company offers a comprehensive suite of cognitive services, encompassing project and data management, scientific consulting, statistical interpretation, acquisition of assessment tools, rater training, and monitoring solutions. It operates through two primary divisions: Clinical Trials and Healthcare. The Clinical Trials segment delivers specialized technology and related support to pharmaceutical and biotechnology companies, enabling them to precisely measure the impact of diseases, medications, medical devices, or other interventions on human participants in clinical studies. Conversely, its Healthcare division supplies Cognigram, a standardized and routine testing system designed to assist primary care providers and hospitals in the early identification of cognitive impairment. As of June 30, 2022, Cogstate had contributed to approximately 1,800 academic research endeavors.
—
Cogstate Limited, a neuroscience technology firm established in 1999 and headquartered in Melbourne, Australia, specializes in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. The company offers a comprehensive suite of cognitive services, encompassing project and data management, scientific consulting, statistical interpretation, acquisition of assessment tools, rater training, and monitoring solutions. It operates through two primary divisions: Clinical Trials and Healthcare. The Clinical Trials segment delivers specialized technology and related support to pharmaceutical and biotechnology companies, enabling them to precisely measure the impact of diseases, medications, medical devices, or other interventions on human participants in clinical studies. Conversely, its Healthcare division supplies Cognigram, a standardized and routine testing system designed to assist primary care providers and hospitals in the early identification of cognitive impairment. As of June 30, 2022, Cogstate had contributed to approximately 1,800 academic research endeavors.
—
Daily adjusted close
Cogstate Limited, a neuroscience technology firm established in 1999 and headquartered in Melbourne, Australia, specializes in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. The company offers a comprehensive suite of cognitive services, encompassing project and data management, scientific consulting, statistical interpretation, acquisition of assessment tools, rater training, and monitoring solutions. It operates through two primary divisions: Clinical Trials and Healthcare. The Clinical Trials segment delivers specialized technology and related support to pharmaceutical and biotechnology companies, enabling them to precisely measure the impact of diseases, medications, medical devices, or other interventions on human participants in clinical studies. Conversely, its Healthcare division supplies Cognigram, a standardized and routine testing system designed to assist primary care providers and hospitals in the early identification of cognitive impairment. As of June 30, 2022, Cogstate had contributed to approximately 1,800 academic research endeavors.